Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease
Open Access
- 25 March 2025
- journal article
- Published by Elsevier in JACC: Advances
- Vol. 4 (4) , 101674
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without DiabetesJAMA, 2022
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Incidence of Type 1 diabetes mellitus and effect on mortality in young patients with congenital heart defect – A nationwide cohort studyInternational Journal of Cardiology, 2020
- Prevalence, Risk Factors, and Impact of Obstructive Sleep Apnea in Adults with Congenital Heart DiseasePediatric Cardiology, 2020
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsDiabetes & Metabolism, 2019
- Liraglutide and Glycaemic Outcomes in the LEADER TrialDiabetes Therapy, 2018
- Body Weights in Adults With Congenital Heart Disease and the Obesity FrequencyThe American Journal of Cardiology, 2017
- Risk Estimates for Atherosclerotic Cardiovascular Disease in Adults With Congenital Heart DiseaseThe American Journal of Cardiology, 2017
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 DiabetesJAMA, 2015